Market Cap
$24.6B
INCY
INCYTE CORP
$115.30 ▼ -1.57%
Prev close $117.14Market cap$24.6B
ConsensusHold
12-mo target$128.48 (+11.4%)
▲ Neutral
Analyst conviction 5/10
Insider Selling Cluster (4 insiders)High Impact Filing (7/10)30 New Institutional Positions20 Institutional Exits Biotech & Drug Discovery
Snapshot
The big-picture read on INCY right now — valuation, ownership and activity at a glance.
Cap Size
Large Cap
Analyst Consensus
Buy (51%)
Inst. Holders
50 funds
Inst. Value
$18.1B
Inst. Activity
30 buys / 20 sells
Insider Activity
$0.00 buy / $14.7M sell
Insider Net $
-$14.7M
SEC Reports
9
Price chart 30d -9.9%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 1, 2026 short_volume
Short Volume: INCY — 64.1% short (0.7M / 1.1M)
Short: 673,483 | Exempt: 4,495 | TRF Vol: 1,050,641 | Short Ratio: 64.1% | Off-exchange volume (dark
Sep 25, 2026 Event
ATEBRIOZ
Original Approval — Type 1 - New Molecular Entity — TABLET
Sep 22, 2026 Insider
Gardner David H surrendered for taxes 920 shares
EVP, Chief Strategy Officer @ $126.93 ($116.8K)
Sep 15, 2026 Insider
CAGNONI PABLO J acquired via exercise 2,957 shares
President, Global Head of R&D @ $61.76 ($182.6K)
Sep 15, 2026 Insider
Aug 15, 2026 SEC CAGNONI PABLO J acquired via exercise 9,233 shares
President, Global Head of R&D @ $71.93 ($664.1K)
Two top R&D executives at Incyte sold a combined $1.57M in stock over a 7-day window. President Pablo Cagnoni sold $1.30
CLUSTER — Impact 4/10
Two senior R&D executives at Incyte (President and Chief Scientific Officer) sold a combined $2.18M of stock in the week
CLUSTER — Impact 2/10
The CSO and President of R&D at Incyte sold a combined $2.16M in open-market shares in the week following the Q2 2026 ea
CLUSTER — Impact 3/10
Analyst ratings buy % -3.8%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
51% rate it Buy or better · 35 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Oct 1, 2026 | Wells Fargo | MAINTAIN | Equal-Weight | 54% |
| Sep 28, 2026 | JP Morgan | MAINTAIN | Neutral | 55% |
| Sep 28, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | 43% |
| Sep 22, 2026 | RBC Capital | REITERATE | Sector Perform | 55% |
| Aug 20, 2026 | Canaccord Genuity | INITIATE | Buy | 47% |
| Aug 20, 2026 | HC Wainwright & Co. | REITERATE | Buy | 43% |
| Aug 17, 2026 | Piper Sandler | MAINTAIN | Overweight | 54% |
| Aug 4, 2026 | Mizuho | MAINTAIN | Outperform | 52% |
| Aug 3, 2026 | Leerink Partners | MAINTAIN | Outperform | 49% |
| Aug 3, 2026 | HC Wainwright & Co. | REITERATE | Buy | 43% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 8 | 10 | 17 | 0 | 0 | 51% | |
| Aug 1, 2026 | 8 | 9 | 16 | 0 | 0 | 52% | |
| Jul 1, 2026 | 8 | 9 | 16 | 0 | 0 | 52% | |
| Jun 1, 2026 | 8 | 8 | 18 | 1 | 0 | 46% | |
| May 1, 2026 | 8 | 8 | 16 | 1 | 0 | 48% | |
| Apr 1, 2026 | 8 | 8 | 16 | 1 | 0 | 48% | |
| Mar 1, 2026 | 9 | 8 | 15 | 1 | 0 | 52% | |
| Feb 1, 2026 | 9 | 7 | 15 | 1 | 0 | 50% |
Price targets
Where 23 covering analysts think INCY trades over the next 12 months.
$128.48 +11.4% upside Buy
Current$115.30 Low$86.00 Median$130.00 High$155.00 23 analysts
$86.00$155.00
Analyst rating Buy· 2.3/5 as of Oct 2, 2026
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
9 SEC filing reports analyzed · 2 bullish, 1 bearish, 1 mixed, 5 neutral · avg impact 4.0/10.
BEARISHCLUSTER4/10
Two top R&D executives at Incyte sold a combined $1.57M in stock over a 7-day window. President Pabl
Aug 15, 2026
NEUTRALCLUSTER2/10
Two senior R&D executives at Incyte (President and Chief Scientific Officer) sold a combined $2.18M
Aug 7, 2026
NEUTRALCLUSTER3/10
The CSO and President of R&D at Incyte sold a combined $2.16M in open-market shares in the week foll
Aug 5, 2026
MIXED8-K6/10
Incyte reported Q2 2026 GAAP diluted EPS of $2.81 (vs consensus $2.15, +30.7% beat) and total revenu
Jul 28, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Oct 1, 2026
Clinical Trial
INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders
Phase Phase 2 — COMPLETED
Oct 1, 2026
short_volume
Short Volume: INCY — 64.1% short (0.7M / 1.1M)
Short: 673,483 | Exempt: 4,495 | TRF Vol: 1,050,641 | Short Ratio: 64.1% | Off-exchange volume (dark pool + OTC)
Sep 30, 2026
short_volume
Short Volume: INCY — 66.9% short (0.3M / 0.5M)
Short: 335,849 | Exempt: 1,372 | TRF Vol: 502,110 | Short Ratio: 66.9% | Off-exchange volume (dark pool + OTC)
Sep 29, 2026
Clinical Trial
Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)
Phase Phase 3 — COMPLETED
Sep 29, 2026
short_volume
Short Volume: INCY — 72.5% short (0.4M / 0.6M)
Short: 434,442 | Exempt: 61,361 | TRF Vol: 599,259 | Short Ratio: 72.5% | Off-exchange volume (dark pool + OTC)
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $-3.51 | $-4.16–$-2.34 | -255.2% | -1.0% | 0↑ 8↓ | $1.5B | 16 |
| Next Q | $1.95 | $1.62–$2.56 | 8.3% | +0.1% | 3↑ 5↓ | $1.5B | 16 |
| Current FY | $3.42 | $2.71–$4.42 | -49.7% | -1.6% | 0↑ 11↓ | $5.9B | 19 |
| Next FY | $8.81 | $7.53–$9.90 | 157.4% | -1.4% | 2↑ 9↓ | $6.3B | 20 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $-3.507 | — |
| 7d ago | $-3.472 | -0.035 |
| 30d ago | $-3.472 | -0.035 |
| 60d ago | $-3.433 | -0.074 |
| 90d ago | $1.482 | -4.989 |
Institutional ownership
Which big funds own INCY (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $18.1B total value (159,428,181 shares) as of 2026-Q2. Top holders: BAKER, BlackRock,, DODGE. Net buying activity: 30 institutions added/increased vs 20 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| BAKER BROS. ADVISORS LP | 30,762,330 | $3.5B | 19.3% | — |
| BlackRock, Inc. | 18,032,718 | $2.0B | 11.3% | — |
| DODGE & COX | 11,957,326 | $1.4B | 7.5% | — |
| VANGUARD CAPITAL MANAGEMENT LLC | 11,024,289 | $1.2B | 6.9% | — |
| STATE STREET CORP | 9,722,336 | $1.1B | 6.1% | — |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 7,791,091 | $883.2M | 4.9% | — |
| AQR CAPITAL MANAGEMENT LLC | 5,320,901 | $603.2M | 3.3% | — |
| GEODE CAPITAL MANAGEMENT, LLC | 4,750,735 | $536.5M | 3.0% | — |
| Invesco Ltd. | 4,080,461 | $462.6M | 2.6% | — |
| WELLINGTON MANAGEMENT GROUP LLP | 3,575,521 | $405.3M | 2.2% | — |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| HSBC HOLDINGS PLC | DOUBLED | 582,368 | 1,307,743 | +124.6% | $148.3M |
| NORGES BANK | NEW | — | 1,119,107 | — | $126.9M |
| PANAGORA ASSET MANAGEMENT INC | TRIM | 1,210,909 | 881,889 | -27.2% | $100.0M |
| JPMORGAN CHASE & CO | ADD | 497,042 | 761,690 | +53.2% | $87.3M |
| UBS Group AG | TRIM | 1,138,004 | 767,924 | -32.5% | $87.1M |
| JACOBS LEVY EQUITY MANAGEMENT, INC | TRIM | 1,717,978 | 731,774 | -57.4% | $83.0M |
| BANK OF AMERICA CORP /DE/ | TRIM | 915,527 | 676,191 | -26.1% | $76.7M |
| LOS ANGELES CAPITAL MANAGEMENT LLC | TRIM | 2,144,847 | 578,986 | -73.0% | $65.6M |
| SEI INVESTMENTS CO | TRIM | 714,558 | 498,013 | -30.3% | $56.5M |
| Vinva Investment Management Ltd | ADD | 300,405 | 462,843 | +54.1% | $53.1M |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
7 insiders, 50 transactions. Net -$14.7M — $0.00 bought, $14.7M sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 22, 2026 | Gardner David H | EVP, Chief Strategy Officer | TAX W/H | 920 | $126.93 | $116.8K |
| Sep 15, 2026 | CAGNONI PABLO J | President, Global Head of R&D | EXERCISE | 2,957 | $61.76 | $182.6K |
| Sep 15, 2026 | CAGNONI PABLO J | President, Global Head of R&D | EXERCISE | 9,233 | $71.93 | $664.1K |
| Sep 15, 2026 | CAGNONI PABLO J | President, Global Head of R&D | SELL | 13,985 | $120.49 | $1.7M |
| Sep 15, 2026 | CAGNONI PABLO J | President, Global Head of R&D | EXERCISE | 4,551 | $61.18 | $278.4K |
| Sep 15, 2026 | CAGNONI PABLO J | President, Global Head of R&D | SELL | 9,233 | $120.50 | $1.1M |
| Sep 15, 2026 | CAGNONI PABLO J | President, Global Head of R&D | EXERCISE | 6,477 | $64.25 | $416.1K |
| Aug 25, 2026 | Basi Ramitpal K | EVP, Human Resources | TAX W/H | 504 | $129.72 | $65.4K |
| Aug 19, 2026 | CAGNONI PABLO J | President, Global Head of R&D | SELL | 10,801 | $125.56 | $1.4M |
| Aug 12, 2026 | CAGNONI PABLO J | President, Global Head of R&D | SELL | 10,803 | $120.04 | $1.3M |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for INCY.
Shares short
9,981,369
Settlement Sep 15, 2026
Change vs prior
+6.6%
Semi-monthly cycle
Days to cover
7.3
At avg daily volume
Of shares outstanding
≈4.9%
Estimate — not % of float
All INCY filing & press-release reports (9)
- CLUSTER reportAug 15, 2026
- CLUSTER reportAug 7, 2026
- CLUSTER reportAug 5, 2026
- 8-K reportJul 28, 2026
- CLUSTER reportJul 27, 2026
- CLUSTER reportJul 21, 2026
- 8-K reportJun 8, 2026
- DEFA14A reportMay 27, 2026
- INST-CLUSTER reportFeb 28, 2026